Riskpilot← Back to searchSign inGet full accessNORIMUN AS
ASActiveOrg 914136830C/O Felleskjøpet Agri Sa Skansen,Nedre Ila 20, 7018 TrondheimForskning og utviklingsarbeid innen bioteknologi · NACE 72110Est. 20141 employees
Revenue 2023
NOK 1,1M
+368% vs 2022
EBITDA margin
-90.1%
+67% vs 2022
Equity ratio
75.2%
Financial strength
Net profit 2023
NOK -1,2M
+86% vs 2022
| Revenue | NOK 1,1M | +368% |
| EBITDA | NOK -958K | +67% |
| Net profit | NOK -1,2M | +86% |
| Total assets | NOK 1,4M | -73% |
| Equity | NOK 1,1M | -53% |
| Employees | 1 | — |
Legal name
NORIMUN AS
Org number
914136830
Legal form
Aksjeselskap
NACE code
72110 · Forskning og utviklingsarbeid innen bioteknologi
Founded
1. oktober 2014
Share capital
NOK 1 244 253
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Daglig leder og styrets leder i fellesskap.
Company purpose
Å utvikle ingredienser, produkter, teknologi og tjenester knyttet til igy tilknyttet funksjonell ernæring og passiv immunisering, innen markeder for akva- og husdyrproduksjon samt human ernæring, helseprodukter, legemidler og det som naturlig inn under dette.
Address
C/O Felleskjøpet Agri Sa Skansen,Nedre Ila 20, 7018 Trondheim
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 241 | 3 122 | 600 | 1 932 | 1 052 | 317 | 227 | 1 062 |
| Staff expenses | −0 | −0 | −12 | −0 | −3 | −1 | −138 | −881 | −1 031 | −799 |
| EBITDA | −28 | −74 | −617 | 1 810 | −238 | 136 | −1 025 | −1 749 | −2 935 | −958 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −14 | −33 | −5 324 | −171 |
| EBIT | −28 | −74 | −617 | 1 810 | −238 | 136 | −1 038 | −1 782 | −8 259 | −1 129 |
| Net financials | 0 | 0 | −0 | 0 | −4 | 1 | 0 | −2 450 | −47 | −74 |
| Profit before tax | −27 | −74 | −617 | 1 810 | −243 | 138 | −1 038 | −4 232 | −8 306 | −1 203 |
| Tax | −0 | −0 | −0 | 149 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −27 | −74 | −617 | 1 661 | −243 | 138 | −1 038 | −4 232 | −8 306 | −1 203 |
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 89 | 31 | 2 527 | 4 554 | 4 664 | 4 942 | 12 114 | 12 537 | 5 262 | 1 407 |
| Equity | 67 | −7 | 2 375 | 4 037 | 3 794 | 4 307 | 3 569 | −663 | 2 261 | 1 058 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 7 000 | 12 000 | 0 | 0 |
| Short-term debt | 22 | 39 | 152 | 517 | 869 | 635 | 1 545 | 1 201 | 3 001 | 349 |
| Total debt | 22 | 39 | 152 | 517 | 869 | 635 | 8 545 | 13 201 | 3 001 | 349 |
EBITDA margin
-90.1%
This company
15.8%
Market median
-670% vs market
20142023
Equity ratio
75.2%
This company
38.2%
Market median
+97% vs market
20142023
Return on equity
-113.7%
This company
18.4%
Market median
-718% vs market
20142023
Net profit margin
-113.3%
This company
8.1%
Market median
-1499% vs market
20142023
Asset turnover
0.75×
This company
1.12×
Market median
-33% vs market
20142023
Debt / equity
0.33×
This company
0.62×
Market median
+47% vs market
20142023
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-08-06 – 2014-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HO Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Felleskjøpet Forutvikling As | Company | 64.3% | 64.3% | 2024 |
Novelfish As | Company | 23.8% | 23.8% | 2024 |
Oreo As | Company | 11.9% | 11.9% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Oninvest As
NORIMUN AS Board members of NORIMUN AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hallgeir Olsen | Chief Executive Officer | 0 companies |
| Ralf Günter Onken | Board of Directors | 0 companies |
| Knut Kvitvang Røflo | Board of Directors | 0 companies |
| Jo Anders Hoff Moflag | Board of Directors | 0 companies |
| Per Olav Skjervold | Chairman | 0 companies |
| Øystein Evensen | Board of Directors | 0 companies |
| Jan Ove Morlandstø | Board of Directors | 0 companies |
| Kari Ljøkjel | Board of Directors | 0 companies |